Takeda has lifted the lid on the phase 3 win for its next-generation claudin18.2 drug, with the antibody-drug conjugate (ADC) ...

For more than two centuries, forensic pathologists have puzzled over a striking autopsy finding: clots in the heart and large vessels that look like yellow chicken fat, dense with lipids and clearly ...

The field of medicine is vast, and there is no limit to its depth. If you get caught up in the depths, you might never come ...

Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically ...

A million-cell atlas identifies distinct human neutrophil states linked to infection, cancer, sex, metabolic health and mortality, while highlighting the need for prospective validation.

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new Phase III data for investigational fenebrutinib in multiple sclerosis (MS), demonstrating reduced markers of ...

Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protectionStructural modeling provides new insight into ...

I am currently hospitalized for a threatened miscarriage due to abdominal pain and bleeding at 13 weeks. Today is a record of ...

The Decades-Long Journey Behind the First Approved Telomerase Inhibitor / cancer, Cancer Drug Development, European Medicines ...

Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan ...

The marker appears on routine blood panels, yet the number can tell two very different stories about your health.

Researchers developed a single-cell atlas of one million human neutrophils, identifying distinct immune cell populations and ...